World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
42564
World Ranking
11562
National Ranking
5933

Overview

Mark A. Socinski is affiliated with the University of North Carolina at Chapel Hill in the United States. The primary field of study is Medicine, with a significant focus on Oncology and Pulmonary and Respiratory Medicine. Their research also spans Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The scientist's work centers on several key topics, including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics

Mark A. Socinski has been published extensively across multiple venues. Frequent publication platforms include:

  • UNC Libraries
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Clinical Lung Cancer

Their recent papers reflect ongoing contributions to clinical oncology and lung cancer research. Notable publications include:

  • "Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial," 2020, Journal of Thoracic Oncology
  • "IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC," 2021, Journal of Thoracic Oncology
  • "Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial," 2020, Journal of Thoracic Oncology
  • "IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain," 2021, Journal of Thoracic Oncology
  • "Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer," 2023, JAMA Oncology

Collaboration is a part of Mark A. Socinski's research approach, working with frequent co-authors including:

  • Thomas E. Stinchcombe
  • Makoto Nishio
  • Robert M. Jotte
  • Federico Cappuzzo
  • Martin Reck

Best Publications

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    Mark A. Socinski;Igor Bondarenko;Nina A. Karaseva;Anatoly M. Makhson

  • Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression

    Karen S. Antman;James D. Griffin;Anthony Elias;Mark A. Socinski

  • GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN

    MarkA. Socinski;Anthony Elias;Lowell Schnipper;StephenA. Cannistra

  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

    Alice T Shaw;Leena Gandhi;Shirish Gadgeel;Gregory J Riely

  • Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

    Jean Yves Douillard;Frances A. Shepherd;Vera Hirsh;Tony Mok

  • Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Charles Butts;Mark A Socinski;Paul L R Mitchell;Nick Thatcher

  • Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

    Mark A. Socinski;Michael J. Schell;Amy Peterman;Kamal Bakri

  • Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer

    Daniel B. Fried;David E. Morris;Charles Poole;Julian G. Rosenman

  • Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    David Planchard;Tae Min Kim;Julien Mazieres;Elisabeth Quoix

  • Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    Robert Jotte;Federico Cappuzzo;Ihor Vynnychenko;Daniil Stroyakovskiy

  • PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

    Jyoti D. Patel;Mark A. Socinski;Edward B. Garon;Craig H. Reynolds

  • Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

    Mark A. Socinski;Silvia Novello;Julie R. Brahmer;Rafael Rosell

  • Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

    Kyle Wang;Michael J. Eblan;Allison M. Deal;Matthew Lipner

  • Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

    Nick Thatcher;Fred R Hirsch;Alexander V Luft;Aleksandra Szczesna

  • Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts

    D. Neil Hayes;Stefano Monti;Giovanni Parmigiani;C. Blake Gilks

Frequent Co-Authors

Martin Reck
Martin Reck LungenClinic Grosshansdorf
Ramaswamy Govindan
Ramaswamy Govindan Washington University in St. Louis
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Corey J. Langer
Corey J. Langer University of Pennsylvania
Nick Thatcher
Nick Thatcher University of Manchester
Silvia Novello
Silvia Novello University of Turin
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Frank C. Detterbeck
Frank C. Detterbeck Yale University
Everett E. Vokes
Everett E. Vokes University of Chicago
Tony Mok
Tony Mok Chinese University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a variety of online degree options and career paths in healthcare. Many students look for flexible, accredited programs to balance education with work or family commitments. Entry points include options like lpn online programs, which offer a fast track to licensure and a career in nursing.

Advanced nursing degrees, such as the DNP (Doctor of Nursing Practice), are also available fully online. Students searching for convenience and efficiency can explore dnp online programs and find options tailored to different schedules and career goals. For those aiming to expedite their studies further, some institutions feature the shortest dnp program with condensed coursework and quicker timelines to graduation.

Mental health is a growing specialty, and the shortest pmhnp program provides a streamlined route to becoming a Psychiatric Mental Health Nurse Practitioner. Each pathway offers different benefits, letting you align your education with your career aspirations in medicine and healthcare.

Best Scientists Citing Mark A. Socinski

Trending Scientists

Recently Published Articles